161 patients treated with septoplastic operations for nasal stenosis were examined 25–64 months postoperatively. Surgery was inadequate in 32 cases (20%); in 23 this was due to the septum operation itself, in 9 to unsatisfactory or no correction of the alar insufficiency. Preoperative anterior dislocations were corrected in 64 of 76 cases, deflection of the nose in 43 of 75 cases. Late complications were few: anterior dislocations in 3 cases; small columellar retractions in 7 cases; small septal perforations in 4 cases, and saddle nose deformity in 3 cases. 35% of the patients were not satisfied with the result, but in 14 patients (9%) this was not justified according to our examination. In a further 11 % the reasons for dissatisfaction were not related to the result of the operation.
The efficacy of diclofenac suppositories was estimated in a two-centre, double-blind, placebo-controlled study comprising 97 patients (47 in the diclofenac group and 50 in the placebo group). The series from the two centres and patients in the two treatment groups were comparable. Immediately postoperatively, the patients received 100 mg diclofenac, followed by 50 mg in the evening and 50 mg in the morning after the operation, or placebo suppositories. The efficacy was assessed both by the patients and by the staff by marking on a visual analogue scale. Statistical analyses showed that diclofenac has a significant (p less than 0.001) effect on the pain associated with swallowing and on the general condition of the patients. The therapeutic gain was calculated to 50%. As a consequence of this study, treatment with diclofenac has been introduced in both ENT departments.
AimsTo evaluate the injection success and user perception of a shield‐triggered pen‐injector mechanism.MethodsThe trial (http://ClinicalTrials.gov NCT02627287) was an exploratory, two‐centre, one‐visit, open‐label, randomized controlled trial conducted in Germany in 150 injection‐experienced individuals with type 1 or type 2 diabetes. Participants self‐administered subcutaneous injections of a placebo solution using a prototype shield‐triggered pen‐injector, DV3316 (Novo Nordisk, Bagsvaerd, Denmark), and FlexPen (Novo Nordisk, Bagsvaerd, Denmark). Injection success was evaluated on a yes/no basis by the investigator. Participant confidence, leakage of fluid and pain were evaluated after each injection. Pain and device experience were assessed after completion of all injections with each pen‐injector. Overall preference was assessed after completion of all injections with both pen‐injectors.ResultsInjection success was high with both pen‐injectors (97.0%, DV3316 vs 99.7%, FlexPen). Participant confidence in dose delivery was similar for the two devices (88% of injections with DV3316 vs 81% with FlexPen were scored as “extremely confident”). The median injection pain score on a visual analogue scale (0‐100) was 3 with DV3316 vs 4 with FlexPen after each injection, and 4 with DV3316 vs 5 with FlexPen after all injections with each device. After all injections were completed, 55% of participants reported an overall preference for DV3316 vs 21% for FlexPen.ConclusionThis study demonstrates that injection‐experienced individuals can achieve a high injection success rate with a shield‐triggered pen‐injector, with similar patient confidence and injection pain compared with FlexPen.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.